Last reviewed · How we verify
Seretide 500 Accuhaler
Seretide 500 Accuhaler is a Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) Small molecule drug developed by University of Southampton. It is currently FDA-approved for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.
Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | Seretide 500 Accuhaler |
|---|---|
| Sponsor | University of Southampton |
| Drug class | Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) |
| Target | Beta-2 adrenergic receptor; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Fluticasone propionate is a corticosteroid that binds glucocorticoid receptors to suppress inflammatory cytokine production and reduce airway edema and mucus secretion. Together, they provide both rapid symptom relief and long-term control of airway obstruction and inflammation.
Approved indications
- Asthma maintenance therapy
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Oral candidiasis
- Hoarseness
- Muscle cramps
Key clinical trials
- Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial (PHASE4)
- Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma (PHASE4)
- A Study in Patients With Chronic Obstructive Pulmonary Disease (PHASE3)
- A Study in Patients With Asthma (PHASE3)
- Flutiform® Compared With Seretide® in the Treatment of COPD (PHASE2, PHASE3)
- Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (PHASE4)
- An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease (PHASE4)
- Add-on Salmeterol Versus Montelukast in Arg/Arg-16 Asthmatics (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Seretide 500 Accuhaler CI brief — competitive landscape report
- Seretide 500 Accuhaler updates RSS · CI watch RSS
- University of Southampton portfolio CI
Frequently asked questions about Seretide 500 Accuhaler
What is Seretide 500 Accuhaler?
How does Seretide 500 Accuhaler work?
What is Seretide 500 Accuhaler used for?
Who makes Seretide 500 Accuhaler?
What drug class is Seretide 500 Accuhaler in?
What development phase is Seretide 500 Accuhaler in?
What are the side effects of Seretide 500 Accuhaler?
What does Seretide 500 Accuhaler target?
Related
- Drug class: All Long-acting beta-2 agonist / inhaled corticosteroid combination (LABA/ICS) drugs
- Target: All drugs targeting Beta-2 adrenergic receptor; glucocorticoid receptor
- Manufacturer: University of Southampton — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Asthma maintenance therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Compare: Seretide 500 Accuhaler vs similar drugs
- Pricing: Seretide 500 Accuhaler cost, discount & access